Abstract
Back pain changes the patients’ life, decreasing its quality and disturbing professional activity.
The aim of the study was to assess the impact of therapy with AMBENIUM® parenteral on restoration of functioning in patients with back pain under conditions of actual clinical practice.
Materials and methods. The data of 100 patients acquired during the non-interventional multicenter trial were analyzed. The following parameters were assessed: pain severity on visual analogue scale (VAS), muscle syndrome index, Roland-Morris Disability Questionnaire score.
Results. After treatment the changes in pain severity on VAS were reported (mean ± standard deviation, median, cm): by -1.8±1.50, -1.0 after
2 h; by -5.8±1.84, -6.0 after 24 h; by -6.2±1.58, -6.0 after 72 h (р<0.0001); the share of responder patients was as follows (decrease on VAS ≤50%): 84% (95% CI 75.0–91.0) after 24 h, 94% (95% CI 87.0–98.0; р=0.0016) after 72 h. The analysis of the Roland-Morris Disability Questionnaire scores showed the following (mean ± standard deviation, median, points): 12.2±3.83, 12.0 before drug administration; 7.9±3.69, 7.0 after 2 h; 3.4±2.95, 2.5 after 24 h; 2.3±2.32, 1.0 after 72 h.
Conclusion. The study conducted has shown that pain has a significant effect on the functioning of patients with low back pain. A single injection of AMBENIUM® parenteral makes it possible to improve functional recovery in patients with back pain against the background of pain management and muscle syndrome severity reduction.
Keywords: AMBENIUM® parenteral, back pain, impaired functioning, quality of life.
The aim of the study was to assess the impact of therapy with AMBENIUM® parenteral on restoration of functioning in patients with back pain under conditions of actual clinical practice.
Materials and methods. The data of 100 patients acquired during the non-interventional multicenter trial were analyzed. The following parameters were assessed: pain severity on visual analogue scale (VAS), muscle syndrome index, Roland-Morris Disability Questionnaire score.
Results. After treatment the changes in pain severity on VAS were reported (mean ± standard deviation, median, cm): by -1.8±1.50, -1.0 after
2 h; by -5.8±1.84, -6.0 after 24 h; by -6.2±1.58, -6.0 after 72 h (р<0.0001); the share of responder patients was as follows (decrease on VAS ≤50%): 84% (95% CI 75.0–91.0) after 24 h, 94% (95% CI 87.0–98.0; р=0.0016) after 72 h. The analysis of the Roland-Morris Disability Questionnaire scores showed the following (mean ± standard deviation, median, points): 12.2±3.83, 12.0 before drug administration; 7.9±3.69, 7.0 after 2 h; 3.4±2.95, 2.5 after 24 h; 2.3±2.32, 1.0 after 72 h.
Conclusion. The study conducted has shown that pain has a significant effect on the functioning of patients with low back pain. A single injection of AMBENIUM® parenteral makes it possible to improve functional recovery in patients with back pain against the background of pain management and muscle syndrome severity reduction.
Keywords: AMBENIUM® parenteral, back pain, impaired functioning, quality of life.
For citation: Kurilchenko D.S., Kazakova M.A., Kupryashkina Yu.G., Feoktistova M.V., Kryzhanovsky S.M., Chukanova E.I. Impaired functioning in patients with back pain. Clinical review for general practice. 2025; 6 (4): 28–32 (In Russ.). DOI: 10.47407/kr2025.6.4.00591
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
